Theralase Technologies Inc. announced that effective January 15, 2013, Michael Jewett MD, FRCSC, FACS has elected to join its Medical and Scientific Advisory Board. Dr. Michael Jewett is currently a Professor of Surgery in the Division of Urology at the University of Toronto, a member of the Department of Surgical Oncology at Princess Margaret Cancer Centre and of the Division of Urology at the University Health Network. He is well known for his contributions in the fields of technology assessment and image guided therapy, especially for minimally invasive treatment of kidney and bladder cancer.

Dr. Jewett has been the Principal Investigator/Co-Principal Investigator on over 60 Phase I-Phase III clinical trials and the Lead Principal Investigator of several Cooperative Group Trials. These clinical trials have primarily been focused on proving the safety, efficacy and clinical benefits of technology in the destruction of cancer, with the ultimate gain of achieving Health Canada or FDA clinical approval. He has recently served as Chairman of the Division of Urology at the University of Toronto and of Urology at the University Health Network, which incorporates the Princess Margaret Cancer Centre.